DHFR and IMPDH: Enzymes exploitable as drug targets in pneumocystis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Many classes of drugs have been tested against infections caused by Pneumocystis since the early part of the twentieth century, when the organism was first shown to cause disease. The two most effective therapies identified empirically were the antifolates sulfamethoxazole-trimethoprim in fixed combination and the antiprotozoal diamidine pentamidine. The principal of selective toxicity requires that drugs be targeted to block required processes in pathogenic organisms and that the targeted process be different enough so that the host is unharmed while growth of the pathogenic organism is prevented or the organism is even destroyed. Thus, improvement over these empirically selected agents requires robust biochemical support both to isolate the drug target and to evaluate inhibition of the target in the intact organism. Pneumocystis does not easily lend itself to biochemical study, but in the last few years methods for isolating purified and biochemically active organisms have improved [1-9]. These methods, coupled with the powerful methods of recombinant DNA technology, have facilitated studies directly on drug targets in the organism [10-12].

Original languageEnglish (US)
Title of host publicationPneumocystis Pneumonia
Subtitle of host publicationThird Edition, Revised and Expanded
PublisherCRC Press
Pages607-630
Number of pages24
ISBN (Electronic)9781420030327
ISBN (Print)9780824754518
StatePublished - Jan 1 2004

Fingerprint

Pneumocystis
Pentamidine
Enzymes
Pneumocystis Infections
Pharmaceutical Preparations
Folic Acid Antagonists
Recombinant DNA
Sulfamethoxazole Drug Combination Trimethoprim
Drug-Related Side Effects and Adverse Reactions
Technology
Growth
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Queener, S. (2004). DHFR and IMPDH: Enzymes exploitable as drug targets in pneumocystis. In Pneumocystis Pneumonia: Third Edition, Revised and Expanded (pp. 607-630). CRC Press.

DHFR and IMPDH : Enzymes exploitable as drug targets in pneumocystis. / Queener, Sherry.

Pneumocystis Pneumonia: Third Edition, Revised and Expanded. CRC Press, 2004. p. 607-630.

Research output: Chapter in Book/Report/Conference proceedingChapter

Queener, S 2004, DHFR and IMPDH: Enzymes exploitable as drug targets in pneumocystis. in Pneumocystis Pneumonia: Third Edition, Revised and Expanded. CRC Press, pp. 607-630.
Queener S. DHFR and IMPDH: Enzymes exploitable as drug targets in pneumocystis. In Pneumocystis Pneumonia: Third Edition, Revised and Expanded. CRC Press. 2004. p. 607-630
Queener, Sherry. / DHFR and IMPDH : Enzymes exploitable as drug targets in pneumocystis. Pneumocystis Pneumonia: Third Edition, Revised and Expanded. CRC Press, 2004. pp. 607-630
@inbook{ae5a885dba8d445485557fd5c19bc848,
title = "DHFR and IMPDH: Enzymes exploitable as drug targets in pneumocystis",
abstract = "Many classes of drugs have been tested against infections caused by Pneumocystis since the early part of the twentieth century, when the organism was first shown to cause disease. The two most effective therapies identified empirically were the antifolates sulfamethoxazole-trimethoprim in fixed combination and the antiprotozoal diamidine pentamidine. The principal of selective toxicity requires that drugs be targeted to block required processes in pathogenic organisms and that the targeted process be different enough so that the host is unharmed while growth of the pathogenic organism is prevented or the organism is even destroyed. Thus, improvement over these empirically selected agents requires robust biochemical support both to isolate the drug target and to evaluate inhibition of the target in the intact organism. Pneumocystis does not easily lend itself to biochemical study, but in the last few years methods for isolating purified and biochemically active organisms have improved [1-9]. These methods, coupled with the powerful methods of recombinant DNA technology, have facilitated studies directly on drug targets in the organism [10-12].",
author = "Sherry Queener",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824754518",
pages = "607--630",
booktitle = "Pneumocystis Pneumonia",
publisher = "CRC Press",

}

TY - CHAP

T1 - DHFR and IMPDH

T2 - Enzymes exploitable as drug targets in pneumocystis

AU - Queener, Sherry

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Many classes of drugs have been tested against infections caused by Pneumocystis since the early part of the twentieth century, when the organism was first shown to cause disease. The two most effective therapies identified empirically were the antifolates sulfamethoxazole-trimethoprim in fixed combination and the antiprotozoal diamidine pentamidine. The principal of selective toxicity requires that drugs be targeted to block required processes in pathogenic organisms and that the targeted process be different enough so that the host is unharmed while growth of the pathogenic organism is prevented or the organism is even destroyed. Thus, improvement over these empirically selected agents requires robust biochemical support both to isolate the drug target and to evaluate inhibition of the target in the intact organism. Pneumocystis does not easily lend itself to biochemical study, but in the last few years methods for isolating purified and biochemically active organisms have improved [1-9]. These methods, coupled with the powerful methods of recombinant DNA technology, have facilitated studies directly on drug targets in the organism [10-12].

AB - Many classes of drugs have been tested against infections caused by Pneumocystis since the early part of the twentieth century, when the organism was first shown to cause disease. The two most effective therapies identified empirically were the antifolates sulfamethoxazole-trimethoprim in fixed combination and the antiprotozoal diamidine pentamidine. The principal of selective toxicity requires that drugs be targeted to block required processes in pathogenic organisms and that the targeted process be different enough so that the host is unharmed while growth of the pathogenic organism is prevented or the organism is even destroyed. Thus, improvement over these empirically selected agents requires robust biochemical support both to isolate the drug target and to evaluate inhibition of the target in the intact organism. Pneumocystis does not easily lend itself to biochemical study, but in the last few years methods for isolating purified and biochemically active organisms have improved [1-9]. These methods, coupled with the powerful methods of recombinant DNA technology, have facilitated studies directly on drug targets in the organism [10-12].

UR - http://www.scopus.com/inward/record.url?scp=85057230489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057230489&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057230489

SN - 9780824754518

SP - 607

EP - 630

BT - Pneumocystis Pneumonia

PB - CRC Press

ER -